| Basics |
Evolus, Inc.
Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
|
| IPO Date: |
February 5, 2018 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$432.75M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.37 | 3.12%
|
| Avg Daily Range (30 D): |
$0.15 | 2.25%
|
| Avg Daily Range (90 D): |
$0.16 | 2.09%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
.85M |
| Avg Daily Volume (90 D): |
1.08M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
88 |
| Avg Trade Size (Sh.) (90 D): |
97 |
| Institutional Trades |
| Total Inst.Trades: |
983 |
| Avg Inst. Trade: |
$1.39M |
| Avg Inst. Trade (30 D): |
$1.15M |
| Avg Inst. Trade (90 D): |
$.99M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.15M |
| Avg Closing Trade (30 D): |
$1.32M |
| Avg Closing Trade (90 D): |
$1.02M |
| Avg Closing Volume: |
96.47K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.97
|
$-.27
|
$-.3
|
|
Diluted EPS
|
$-.97
|
$-.27
|
$-.3
|
|
Revenue
|
$ 277.94M
|
$ 69.39M
|
$ 68.52M
|
|
Gross Profit
|
$ 185.18M
|
$ 45.32M
|
$ 46.66M
|
|
Net Income / Loss
|
$ -62M
|
$ -17.14M
|
$ -18.89M
|
|
Operating Income / Loss
|
$ -43.17M
|
$ -10.21M
|
$ -15.17M
|
|
Cost of Revenue
|
$ 92.76M
|
$ 24.07M
|
$ 21.87M
|
|
Net Cash Flow
|
$ -31.93M
|
$ -6.16M
|
$ -19.06M
|
|
PE Ratio
|
|
|
|
|
|
|
